Renovorx, inc. announces $5 million registered direct offering priced at-the-market under nasdaq rules

Los altos, calif.--(business wire)--renovorx, inc. (the “company”) (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the company's common stock (or common stock equivalents) at a purchase price of $3.
RNXT Ratings Summary
RNXT Quant Ranking